Astra Zeneca Vaccine Likely to be Approved in UK Tomorrow

Astra Zenaca has developed a vaccine with Oxford University for Covid 19. The Muslim Times has the latest and the best about vaccines


Oxford Covid vaccine expected to be approved MONDAY as huge efforts ‘pay off’

By Ryan Sabey

Source: The Sun

HUGE efforts to develop a home-grown Covid-19 vaccine have “paid off” — with the new Oxford jab expected to get approval as early as Monday.

The UK’s Vaccines Minister told The Sun on Sunday the massive effort had been heroic and displayed “the best of British at every stage”.

Our world-leading scientists have led the round-the-clock lab to jab mission and have delivered in nine months what normally takes years.

Now regulators have been passed the full data package for the Oxford AstraZeneca vaccine.

The rescue mission, with huge input from researchers and engineers across the UK, will deliver an immediate economic shot in the arm for the nation — and for the health of its people.

Experts working at sites in Newcastle, Essex, Wrexham and in Scotland are all contributing in the race-against-time battle to help young and old.

Vaccines Minister Nadhim Zahawi told The Sun on Sunday: “The heroic efforts of the team at the University of Oxford have paid off, with its home-grown vaccine shown to be effective in older people as well as young.


“From day one of the pandemic, people from across the nation have been working day and night to find a safe and effective Covid-19 vaccine.

“We have seen the best of British at every stage, from our world-leading scientists working around the clock to carry out vital research, to builders and engineers constructing new facilities.

“Manufacturers are boosting their capabilities and hundreds of thousands of people in every corner of the UK are taking part in clinical trials ­­— developing, finding and preparing for a vaccine has involved us all.

“It has and continues to be a truly UK-wide effort and one which showcases what a fantastic nation we are.”

The first injections are expected to be rolled out a week after the new drug gets the go-ahead.

Speaking last week, the lead researcher at Oxford University, Professor Sarah Gilbert, said: “The regulators have to be given their time but I really hope that the moment isn’t too far off.”

Developing and manufacturing the doses has been completed across the country in a mammoth effort.

Scientists at Oxford University spent months working on the vaccine.

And ministers have given £88million since March to help accelerate the project.

The jabs will be manufactured in Oxford and Newcastle with 100 million doses ordered by the Government.

Unlike the Pfizer vaccine, which is already being deployed, it can be stored in a standard fridge rather than at -70C.

Read further

Categories: Vaccine

6 replies

  1. Britain could be free of tight Covid restrictions by the end of February, after Ministers pinpointed the 15 million people who would need vaccinations to end the cycles of crippling lockdowns.

    With the ‘game-changing’ Oxford jab expected to be approved within days, the Government hopes that enough doses will soon be available to inoculate those most vulnerable to coronavirus within weeks.

    Vaccines Minister Nadhim Zahawi told The Sun that approval would likely be granted on Monday, with plans to roll out jabs to the entire country starting January 4, according to The Telegraph.

  2. However, he added that “the early roll-out of vaccines – and the incredible work of our scientists and NHS – means we can now see light at the end of the tunnel.”

    Nearly 200 million doses of the AstraZeneca vaccine will be made before the end of the year, the UK drug manufacturer has said, and more than 700 million globally by the end of March next year.

  3. LONDON (AP) — The head of drugmaker AstraZeneca, which is developing a coronavirus vaccine widely expected to be approved by U.K. authorities this week, said Sunday that researchers believe the shot will be effective against a new variant of the virus driving a rapid surge in infections in Britain.

    AstraZeneca chief executive Pascal Soriot also told the Sunday Times that researchers developing its vaccine have figured out a “winning formula” making the jab as effective as rival candidates.

    Some have raised concern that the AstraZeneca vaccine, which is being developed with Oxford University, may not be as good as the one made by Pfizer already being distributed in the U.K. and other countries. Partial results suggest that the AstraZeneca shot is about 70% effective for preventing illness from coronavirus infection, compared to the 95% efficacy reported by Pfizer and its German partner BioNTech.

    “We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” Soriot said. “I can’t tell you more because we will publish at some point.”

    Britain’s government says its medicines regulator is reviewing the final data from AstraZeneca’s phase three clinical trials. The Times and others have reported that the green light could come by Thursday, and the vaccines can start to be rolled out for the U.K. public in the first week of January.

    Asked about the vaccine’s efficacy against the new variant of coronavirus spreading in the U.K., Soriot said: “So far, we think the vaccine should remain effective. But we can’t be sure, so we’re going to test that.”

    British authorities have blamed the new virus variant for soaring infection rates across the country. They said the variant is much more transmittable, but stress there is no evidence it makes people more ill.

  4. The Oxford-AstraZeneca vaccine is being manufactured locally by the Serum Institute of India, the world’s largest vaccine manufacturer. It says it is producing more than 50 million doses a month.

    The vaccine, which is known as Covishield, is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees. It has been modified to look more like coronavirus – although it can’t cause illness.

  5. Vaccine developers said they are working on a new shot to combat the South African strain of coronavirus after early data suggested AstraZeneca Plc’s product has limited efficacy against mild disease caused by the variant.

    There isn’t yet enough information from research to show whether the Oxford-AstraZeneca vaccine is effective at preventing severe Covid-19 cases, hospitalization and deaths, the company said in a statement.

    Sarah Gilbert, leading the Oxford University-AstraZeneca vaccine program, said work was already under way to adapt the vaccine to deal specifically with the South African variant. The new shot is “very likely” to be available by autumn, she said.

  6. British doctors who spent 102 days treating a cancer survivor for Covid-19 documented how the virus mutated after the man was treated with convalescent plasma.

    The case study suggests the use of blood plasma donated from Covid-19 survivors may have put enough pressure on the virus to force it to evolve. The result: Less susceptibility to immune system antibodies that normally fight off infection, according to the report published Friday in the journal Nature.

    While the convalescent plasma didn’t seem to harm the patient, it offered no clear benefit, said senior author Ravindra Gupta, a professor of clinical microbiology at the Cambridge Institute of Therapeutic Immunology and Infectious Disease. It should be used cautiously in people with chronic immune conditions, he said, preferably in clinical trials or carefully controlled settings.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.